Meridian Bioscience Inc. (VIVO): Price and Financial Metrics


Meridian Bioscience Inc. (VIVO): $32.00

0.01 (+0.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VIVO POWR Grades

  • Quality is the dimension where VIVO ranks best; there it ranks ahead of 95.28% of US stocks.
  • The strongest trend for VIVO is in Value, which has been heading down over the past 178 days.
  • VIVO ranks lowest in Growth; there it ranks in the 8th percentile.

VIVO Stock Summary

  • VIVO's went public 30.79 years ago, making it older than 83.6% of listed US stocks we're tracking.
  • VIVO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 17.36% of US stocks.
  • With a year-over-year growth in debt of -49.48%, MERIDIAN BIOSCIENCE INC's debt growth rate surpasses just 5.69% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to MERIDIAN BIOSCIENCE INC, a group of peers worth examining would be LFUS, FOXF, ISPC, LMAT, and CFMS.
  • Visit VIVO's SEC page to see the company's official filings. To visit the company's web site, go to www.meridianbioscience.com.

VIVO Valuation Summary

  • VIVO's EV/EBIT ratio is 24.5; this is 181.61% higher than that of the median Healthcare stock.
  • VIVO's price/sales ratio has moved up 2.4 over the prior 243 months.

Below are key valuation metrics over time for VIVO.

Stock Date P/S P/B P/E EV/EBIT
VIVO 2022-12-02 4.2 3.8 33.0 24.5
VIVO 2022-12-01 4.2 3.8 33.0 24.4
VIVO 2022-11-30 4.2 3.8 33.0 24.5
VIVO 2022-11-29 4.2 3.8 32.9 24.3
VIVO 2022-11-28 4.2 3.8 32.6 24.1
VIVO 2022-11-25 4.2 3.8 32.9 24.4

VIVO Growth Metrics

    The 2 year revenue growth rate now stands at 66.31%.
  • Its 3 year cash and equivalents growth rate is now at 13.99%.
  • Its year over year net income to common stockholders growth rate is now at -28.32%.
VIVO's revenue has moved up $147,816,000 over the prior 67 months.

The table below shows VIVO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 343.547 94.853 43.411
2022-03-31 339.287 91.346 62.418
2021-12-31 313.32 77.299 59.968
2021-09-30 317.896 66.865 71.407
2021-06-30 305.845 68.682 71.243
2021-03-31 327.131 73.752 87.081

VIVO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VIVO has a Quality Grade of B, ranking ahead of 84.82% of graded US stocks.
  • VIVO's asset turnover comes in at 0.713 -- ranking 41st of 682 Pharmaceutical Products stocks.
  • CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with VIVO.

The table below shows VIVO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.713 0.637 0.468
2021-03-31 0.775 0.653 0.560
2020-12-31 0.763 0.636 0.495
2020-09-30 0.685 0.616 0.342
2020-06-30 0.686 0.611 0.339
2020-03-31 0.625 0.585 0.192

VIVO Price Target

For more insight on analysts targets of VIVO, see our VIVO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.00 Average Broker Recommendation 1.17 (Strong Buy)

VIVO Stock Price Chart Interactive Chart >

Price chart for VIVO

VIVO Price/Volume Stats

Current price $32.00 52-week high $34.38
Prev. close $31.99 52-week low $17.20
Day low $31.88 Volume 131,100
Day high $32.20 Avg. volume 497,659
50-day MA $31.96 Dividend yield N/A
200-day MA $29.59 Market Cap 1.40B

Meridian Bioscience Inc. (VIVO) Company Bio


Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is based in Cincinnati, Ohio.


VIVO Latest News Stream


Event/Time News Detail
Loading, please wait...

VIVO Latest Social Stream


Loading social stream, please wait...

View Full VIVO Social Stream

Latest VIVO News From Around the Web

Below are the latest news stories about MERIDIAN BIOSCIENCE INC that investors may wish to consider to help them evaluate VIVO as an investment opportunity.

Meridian Bioscience (VIVO) Q4 Earnings Surpass Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 22, 2022

MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022.

Yahoo | November 22, 2022

BellRing Brands (BRBR) Beats Q4 Earnings Estimates

BellRing Brands (BRBR) delivered earnings and revenue surprises of 6.90% and 6.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 17, 2022

4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire

Most investors would like to see their stock portfolio grow significantly, especially if they have quite a few years left until retirement. Alphabet (NASDAQ: GOOG), Vertex Pharmaceuticals (NASDAQ: VRTX), Eli Lilly and Company (NYSE: LLY), and Meridian Bioscience (NASDAQ: VIVO) all show solid potential to grow your investments significantly. Alphabet's stock has risen 105% over the past five years.

Yahoo | October 7, 2022

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Meridian Bioscience (VIVO) and Neurocrine (NBIX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Travere Therapeutics (TVTX – Research Report), Meridian Bioscience (VIVO – Research Report) and Neurocrine (NBIX – Research Report). Travere Therapeutics (TVTX) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Travere Therapeutics today and set a price target of $42.00. The company's shares closed last Friday at $27.83. According to TipRanks.

Brian Anderson on TipRanks | August 8, 2022

Read More 'VIVO' Stories Here

VIVO Price Returns

1-mo -0.03%
3-mo 0.03%
6-mo 11.11%
1-year 63.27%
3-year 245.57%
5-year 128.02%
YTD 56.86%
2021 9.15%
2020 91.30%
2019 -43.29%
2018 28.02%
2017 -18.01%

Continue Researching VIVO

Want to see what other sources are saying about Meridian Bioscience Inc's financials and stock price? Try the links below:

Meridian Bioscience Inc (VIVO) Stock Price | Nasdaq
Meridian Bioscience Inc (VIVO) Stock Quote, History and News - Yahoo Finance
Meridian Bioscience Inc (VIVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6338 seconds.